INDEX RANK: 15th

Total Impact Score: 9,055.11

Johnson and Johnson is ranked 15th place in our index for 2015. Johnson and Johnson’s drugs have a total impact score of 9,055.11. Johnson and Johnson treats three diseases in our model - roundworm, hookworm, and whipworm - with one drug - Mebendazole (MBD). Johnson and Johnson receives credit for one treatment against roundworm - Mebendazole (MBD). This one drug averted 9,004.29 of the total DALYS for roundworm, which is 2.46% of the worldwide DALYs that we estimate would have been lost due to roundworm in 2015 in the absence of effective treatment. Johnson and Johnson’s drug portfolio placed it 3rd in terms of total averted DALYs for roundworm. Johnson and Johnson receives credit for one treatment against hookworm - Mebendazole (MBD). This one drug averted 3,360.12 of the total DALYS for hookworm, which is 12.12% of the worldwide DALYs that we estimate would have been lost due to hookworm in 2015 in the absence of effective treatment. Johnson and Johnson’s drug portfolio placed it 2nd in terms of total averted DALYs for hookworm. Johnson and Johnson receives credit for one treatment against whipworm - Mebendazole (MBD). This one drug averted 2,275.63 of the total DALYS for whipworm, which is 16.55% of the worldwide DALYs that we estimate would have been lost due to whipworm in 2015 in the absence of effective treatment. Johnson and Johnson’s drug portfolio placed it 3rd in terms of total averted DALYs for whipworm.

Company Score Breakdown:

Key Drugs

Company Information

Johnson & Johnson is a global pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey, and founded by Robert, James and Edward Johnson in 1886. They are divided into three business segments, consumer, medical devices, and pharmaceuticals, focusing their medicine in six therapeutic areas: cardiovascular and metabolism, immunology, infectious disease and vaccines, neuroscience, oncology, and pulmonary hypertension. Major products include Remicade®, Aria®, and Stelara®. J&J’s Bedaquiline Access Program has donated bedaquiline since 2015 and is offering this MDR-TB drug at a lower, non-commercial cost for low-and-middle income nations in order to make it more accessible. They donate about 200 million doses of mebendazole each year to treat worms in underserved regions. They have over 95 products on the Access to Medicines index, are currently running a clinical trial on a potential HIV preventive vaccine regimen, and have announced collaboration with IMTECH to discover new TB medicines. Johnson and Johnson had a revenue of $76.45 billion and approximately 134,000 employees, operating in over 60 countries, in 2017.

Company Report PDF